Frontiers in Neuroscience (Apr 2023)
Association between methionine sulfoxide and risk of moyamoya disease
- Junsheng Li,
- Junsheng Li,
- Junsheng Li,
- Junsheng Li,
- Junsheng Li,
- Peicong Ge,
- Peicong Ge,
- Peicong Ge,
- Peicong Ge,
- Peicong Ge,
- Qiheng He,
- Qiheng He,
- Qiheng He,
- Qiheng He,
- Qiheng He,
- Chenglong Liu,
- Chenglong Liu,
- Chenglong Liu,
- Chenglong Liu,
- Chenglong Liu,
- Chaofan Zeng,
- Chaofan Zeng,
- Chaofan Zeng,
- Chaofan Zeng,
- Chaofan Zeng,
- Chuming Tao,
- Yuanren Zhai,
- Yuanren Zhai,
- Yuanren Zhai,
- Yuanren Zhai,
- Yuanren Zhai,
- Jia Wang,
- Jia Wang,
- Jia Wang,
- Jia Wang,
- Jia Wang,
- Qian Zhang,
- Qian Zhang,
- Qian Zhang,
- Qian Zhang,
- Qian Zhang,
- Rong Wang,
- Rong Wang,
- Rong Wang,
- Rong Wang,
- Rong Wang,
- Yan Zhang,
- Yan Zhang,
- Yan Zhang,
- Yan Zhang,
- Yan Zhang,
- Dong Zhang,
- Dong Zhang,
- Dong Zhang,
- Dong Zhang,
- Dong Zhang,
- Jizong Zhao,
- Jizong Zhao,
- Jizong Zhao,
- Jizong Zhao,
- Jizong Zhao,
- Jizong Zhao
Affiliations
- Junsheng Li
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Junsheng Li
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Junsheng Li
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Junsheng Li
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Junsheng Li
- Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China
- Peicong Ge
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Peicong Ge
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Peicong Ge
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Peicong Ge
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Peicong Ge
- Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China
- Qiheng He
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Qiheng He
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Qiheng He
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Qiheng He
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Qiheng He
- Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China
- Chenglong Liu
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Chenglong Liu
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Chenglong Liu
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Chenglong Liu
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Chenglong Liu
- Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China
- Chaofan Zeng
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Chaofan Zeng
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Chaofan Zeng
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Chaofan Zeng
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Chaofan Zeng
- Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China
- Chuming Tao
- Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
- Yuanren Zhai
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Yuanren Zhai
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Yuanren Zhai
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Yuanren Zhai
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Yuanren Zhai
- Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China
- Jia Wang
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Jia Wang
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Jia Wang
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Jia Wang
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Jia Wang
- Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China
- Qian Zhang
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Qian Zhang
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Qian Zhang
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Qian Zhang
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Qian Zhang
- Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China
- Rong Wang
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Rong Wang
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Rong Wang
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Rong Wang
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Rong Wang
- Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China
- Yan Zhang
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Yan Zhang
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Yan Zhang
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Yan Zhang
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Yan Zhang
- Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China
- Dong Zhang
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Dong Zhang
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Dong Zhang
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Dong Zhang
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Dong Zhang
- Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China
- Jizong Zhao
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Jizong Zhao
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Jizong Zhao
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Jizong Zhao
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Jizong Zhao
- Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China
- Jizong Zhao
- Savaid Medical School, University of the Chinese Academy of Sciences, Beijing, China
- DOI
- https://doi.org/10.3389/fnins.2023.1158111
- Journal volume & issue
-
Vol. 17
Abstract
ObjectiveMethionine sulfoxide (MetO) has been identified as a risk factor for vascular diseases and was considered as an important indicator of oxidative stress. However, the effects of MetO and its association with moyamoya disease (MMD) remained unclear. Therefore, we performed this study to evaluate the association between serum MetO levels and the risk of MMD and its subtypes.MethodsWe eventually included consecutive 353 MMD patients and 88 healthy controls (HCs) with complete data from September 2020 to December 2021 in our analyzes. Serum levels of MetO were quantified using liquid chromatography-mass spectrometry (LC–MS) analysis. We evaluated the role of MetO in MMD using logistic regression models and confirmed by receiver-operating characteristic (ROC) curves and area under curve (AUC) values.ResultsWe found that the levels of MetO were significantly higher in MMD and its subtypes than in HCs (p < 0.001 for all). After adjusting for traditional risk factors, serum MetO levels were significantly associated with the risk of MMD and its subtypes (p < 0.001 for all). We further divided the MetO levels into low and high groups, and the high MetO level was significantly associated with the risk of MMD and its subtypes (p < 0.05 for all). When MetO levels were assessed as quartiles, we found that the third (Q3) and fourth (Q4) MetO quartiles had a significantly increased risk of MMD compared with the lowest quartile (Q3, OR: 2.323, 95%CI: 1.088–4.959, p = 0.029; Q4, OR: 5.559, 95%CI: 2.088–14.805, p = 0.001).ConclusionIn this study, we found that a high level of serum MetO was associated with an increased risk of MMD and its subtypes. Our study raised a novel perspective on the pathogenesis of MMD and suggested potential therapeutic targets.
Keywords
